TY - JOUR
T1 - Basic Science and Pathogenesis
AU - ADNI, Knight Alzheimer Disease Research Center (Knight ADRC), the Dominantly Inherited Alzheimer Network (DIAN), ADNI‐DOD, the Australian Imaging Biomarkers, Lifestyle (AIBL) Study, A4 Study Team, Alzheimer’s Disease Sequencing Project (ADSP)
AU - Wang, Ting Chen
AU - Archer, Derek B.
AU - Ali, Muhammad
AU - Wu, Yiyang
AU - Mormino, Elizabeth
AU - Buckley, Rachel F.
AU - Lee, Annie J.
AU - Saykin, Andrew J.
AU - De Jager, Philip L.
AU - Schneider, Julie A.
AU - Bennett, David A.
AU - Barnes, Lisa L.
AU - Vardarajan, Badri N.
AU - Mayeux, Richard
AU - Kunkle, Brian W.
AU - Bush, William S.
AU - Keene, C. Dirk
AU - Seshadri, Sudha
AU - Sperling, Reisa A.
AU - Vemuri, Prashanthi
AU - Ramanan, Vijay K.
AU - Schellenberg, Gerard D.
AU - Huentelman, Matthew J.
AU - Hamilton-Nelson, Kara L.
AU - Pericak-Vance, Margaret A.
AU - Goate, Alison M.
AU - Haines, Jonathan L.
AU - Montine, Thomas J.
AU - Beecham, Gary W.
AU - Cruchaga, Carlos
AU - Hohman, Timothy J.
AU - Dumitrescu, Logan C.
N1 - Publisher Copyright:
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - BACKGROUND: Genome-wide association studies (GWAS) in Alzheimer's disease (AD) leveraging endophenotypes beyond case/control diagnosis, such as brain amyloid β pathology, have shown promise in identifying novel variants and understanding their potential functional impact. In this study, we leverage two brain amyloid β pathology measurement modalities, PET imaging and neuropathology, to address sample size limitations and to discover novel genetic drivers of disease. METHOD: We conducted a meta-analysis on an amyloid PET imaging GWAS (N = 7,036, 35% amyloid positive, 53.67% female, age = 71) and an autopsy GWAS of brain amyloidosis (N = 6,519, 63.08% amyloid positive, 51.34% female, age at death = 83), both adjusted for covariates including age, sex and principal components of genetic ancestry. All participants in both GWAS were unrelated individuals of European descent. We defined amyloid positivity as moderate or frequent neuritic plaques using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) staging scores within each autopsy cohort. A Gaussian mixture model (GMM) was applied to each amyloid PET imaging cohort to identify the cohort and tracer-specific cut-offs that differentiate amyloid positive and negative populations. RESULT: The genome-wide significant results from the meta-analysis identified three known AD loci (APOE, CR1, and BIN1) and a novel chromosome 17 locus (rs35635959, intergenic, MAF = 0.27, OR = 1.18, p = 1.47 × 10-8). The MAGMA gene-level analysis excluding the APOE region suggests significant associations between rs35635959 and COASY, PLEKHH3, and TUBG2 on chromosome 17, implying the potential roles of these genes on amyloidosis. Functional annotations of rs35635959 leveraging brain eQTL databases indicate its association with differential gene expression of COASY and TUBG2 in AD brains. ROSMAP bulk and single-nucleus RNAseq analyses link TUBG2 downregulation to the higher amyloid burden and AD diagnosis while suggesting such observations are enriched in excitatory and inhibitory neurons, reaching FDR significance. CONCLUSION: This study is the most extensive European GWAS of brain amyloidosis, and our findings replicate known AD loci and identify a possible novel locus (index SNP rs35635959) on chromosome 17. Functional annotations of the novel variant indicate TUBG2, implicating in microtubule organization, warrants further assessment. Ongoing efforts aim to validate these novel effects using independent datasets.
AB - BACKGROUND: Genome-wide association studies (GWAS) in Alzheimer's disease (AD) leveraging endophenotypes beyond case/control diagnosis, such as brain amyloid β pathology, have shown promise in identifying novel variants and understanding their potential functional impact. In this study, we leverage two brain amyloid β pathology measurement modalities, PET imaging and neuropathology, to address sample size limitations and to discover novel genetic drivers of disease. METHOD: We conducted a meta-analysis on an amyloid PET imaging GWAS (N = 7,036, 35% amyloid positive, 53.67% female, age = 71) and an autopsy GWAS of brain amyloidosis (N = 6,519, 63.08% amyloid positive, 51.34% female, age at death = 83), both adjusted for covariates including age, sex and principal components of genetic ancestry. All participants in both GWAS were unrelated individuals of European descent. We defined amyloid positivity as moderate or frequent neuritic plaques using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) staging scores within each autopsy cohort. A Gaussian mixture model (GMM) was applied to each amyloid PET imaging cohort to identify the cohort and tracer-specific cut-offs that differentiate amyloid positive and negative populations. RESULT: The genome-wide significant results from the meta-analysis identified three known AD loci (APOE, CR1, and BIN1) and a novel chromosome 17 locus (rs35635959, intergenic, MAF = 0.27, OR = 1.18, p = 1.47 × 10-8). The MAGMA gene-level analysis excluding the APOE region suggests significant associations between rs35635959 and COASY, PLEKHH3, and TUBG2 on chromosome 17, implying the potential roles of these genes on amyloidosis. Functional annotations of rs35635959 leveraging brain eQTL databases indicate its association with differential gene expression of COASY and TUBG2 in AD brains. ROSMAP bulk and single-nucleus RNAseq analyses link TUBG2 downregulation to the higher amyloid burden and AD diagnosis while suggesting such observations are enriched in excitatory and inhibitory neurons, reaching FDR significance. CONCLUSION: This study is the most extensive European GWAS of brain amyloidosis, and our findings replicate known AD loci and identify a possible novel locus (index SNP rs35635959) on chromosome 17. Functional annotations of the novel variant indicate TUBG2, implicating in microtubule organization, warrants further assessment. Ongoing efforts aim to validate these novel effects using independent datasets.
UR - http://www.scopus.com/inward/record.url?scp=85214590198&partnerID=8YFLogxK
U2 - 10.1002/alz.090566
DO - 10.1002/alz.090566
M3 - Article
C2 - 39751611
AN - SCOPUS:85214590198
SN - 1552-5260
VL - 20
SP - e090566
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -